is based in Berlin
Wolfgang Nedbal, PhD
For more than 25 years experience with Antisense technology; starting career after basic research at the German Cancer Research Center (DKFZ - Heidelberg) he acquired clinical insights at the department of hematology and oncology at the University of Heidelberg; was involved in the first non-commercial clinical Antisense trial in Germany.
Chemistry & Drug Synthesis:
Thomas Rupp, Scientist
Over 30 years of technical experience in oligonucleotide manufacturing and analytics, Thomas Rupp is a very well-recognized expert and go-to-person in the oligonucleotide field; since mid-2013 Thomas Rupp works as an independent technical and regulatory CMC consultant in the field of therapeutic oligonucleotides.
Prof. Georg Sczakiel, PhD
One of major players in the field of academic research and pre-commercial R&D of nucleic acid-based drugs for nearly 30 years; Co-founder of the oligonucleotide therapeutics society (OTS), well established and trustful relationships within academia & industry; Director of the Institute of Molecular Medicine (IMM) of the University of Lübeck, Germany. Transferpreisträger (Preis für beispielgebende Projektaktivitäten im Technologietransfer der Universität zu Lübeck.
Finance & Communication
Alex Zeh, Financial Engineer
With 20 years of working with multinationals as well as technology startup companies in the field of financial, reporting, controlling, management and consulting in EU, US and Gulf countries; currently with a biotch prime standard stock listed R&D company; cares for strategy, partnering, business orientation and financial affairs.